Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · PRECISION BIOSCIENCES INC (DTIL)

Precision BioSciences doses first patient in Phase 1/2 PBGENE-DMD Duchenne trial

Neutral Impact 3 of 5 product/contract Written later

Precision BioSciences said it dosed the first patient in its Phase 1/2 FUNCTION-DMD trial of PBGENE-DMD, a gene-editing treatment for Duchenne muscular dystrophy, at Arkansas Children's Hospital. The company said it expects to report initial safety data by year-end 2026. The filing reports no financial results, so it does not show a change in the company's financial position.

Key points

  • First patient dosed in August 2026 at Arkansas Children's Hospital
  • Study enrolls ambulatory DMD patients aged 2 to 7 with exon 45-55 mutations, which the company says cover up to 60% of boys with DMD
  • Company expects initial safety data by year-end 2026
  • Trial is registered as NCT07429240 on clinicaltrials.gov

The filing

CompanyPRECISION BIOSCIENCES INC (DTIL)
Form8-K, current report
Filed with the SECAug 24, 2026, 7:00 AM ET
Accession number0001628280-26-058512

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 24, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.